β3-Integrins rather than β1-integrins dominate integrin-matrix interactions involved in postinjury smooth muscle cell migration

Circulation

Volumn 97, Issue 18, 1998, Pages 1818-1827

  Slepian, Marvin J ^a   Massia, Stephen P ^b   Dehdashti, Behrooz ^b   Fritz, Anne ^b   Whitesell, Luke ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b NONE

Author keywords

Cell adhesion molecules; Integrins; Restenosis

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CELL ADHESION MOLECULE; CYCLOPEPTIDE; INTEGRIN; ARGINYL-GLYCYL-ASPARTIC ACID; BETA1 INTEGRIN; BETA3 INTEGRIN; FIBRINOGEN RECEPTOR; FIBRONECTIN; GLYCYL ARGINYL ALANYL ASPARTYL SERYL PROLINE; GLYCYL ARGINYL GLYCYL ASPARTYL SERYL PROLINE; GLYCYL-ARGINYL-ALANYL-ASPARTYL-SERYL-PROLINE; GLYCYL-ARGINYL-GLYCYL-ASPARTYL-SERYL-PROLINE; GPENGRGDSPCA; LEUKOCYTE ANTIGEN; OLIGOPEPTIDE; VITRONECTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTERY INJURY; ARTICLE; CAROTID ARTERY SURGERY; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FIBROMUSCULAR DYSPLASIA; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HEART MUSCLE REVASCULARIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RESTENOSIS; VASCULAR SMOOTH MUSCLE; ANIMAL; BALLOON DILATATION; CAROTID ARTERY; CAROTID ARTERY INJURY; CELL ADHESION; CELL CULTURE; CELL MOTION; CHEMISTRY; COMPARATIVE STUDY; INJURY; PATHOLOGY; PHYSIOLOGY; SMOOTH MUSCLE; SPRAGUE DAWLEY RAT; VASCULAR ENDOTHELIUM; WOUND HEALING;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD29; BALLOON DILATATION; CAROTID ARTERIES; CAROTID ARTERY INJURIES; CELL ADHESION; CELL MOVEMENT; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; FIBRONECTINS; FLOW CYTOMETRY; INTEGRIN BETA3; MICROSCOPY, FLUORESCENCE; MUSCLE, SMOOTH; OLIGOPEPTIDES; PLATELET MEMBRANE GLYCOPROTEINS; RATS; RATS, SPRAGUE-DAWLEY; VITRONECTIN; WOUND HEALING;

EID: 0032510595     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.18.1818     Document Type: Article

References (51)

1. Califf RM, Fortin DF, Frid DJ, Harlan WR III, Ohman EM, Bengtson JR, Nelson CL, Tcheng JE, Mark DB, Stack RS. Restenosis after coronary angioplasty: an overview. J Am Coll Cardiol. 1991;17:2B-13B.
2. Casscells W. Migration of smooth muscle and endothelial cells: critical events in restenosis. Circulation. 1993;86:723-729.
3. Isner JM. Vascular remodeling: honey, I think I shrunk the artery. Circulation. 1994;89:2937-2941.
4. Ettinger L, Doljanski F. On the generation of form by the continuous interactions between cells and their extracellular matrix. Biol Rev (Lond). 1992;67:459-489.
5. Huttenlocher A, Sandborg RR, Horwitz AF. Adhesion in cell migration. Curr Opin Cell Biol. 1995;7:697-706.
6. Ruoslahti E. Integrins. J Clin Invest. 1991;87:l-5.
7. Hynes RO. Integrins: variety, versatility, and interactions in cell adhesions. Cell. 1992;69:11-25.
8. Hemler ME. VLA proteins in the integrin family: structures, functions and their roles on leukocytes. Annu Rev Immunol. 1990;8:365-400.
9. Beauvais A, Erickson CA, Groins T, Craig SE, Humphries MJ, Theiry JP, Dufour S. Changes in the fibronectin-specific integrin expression pattern modify the migratory behavior of sarcoma 5180 cells in vitro and in the embryonic environment. J Cell Biol. 1995;128:699-713.
10. 1 integrin synthesis by recombinant platelet-derived growth factor (PDGF-AB) correlates with an enhanced migratory response of human dermal fibroblasts to various extracellular matrix proteins. Exp Cell Res. 1995;220:29-35.
11. Leavesley DI, Ferguson GD, Wayner EA, Cheresh DA. Requirement of the integrin β3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell Biol. 1992;117:1101-1107.
12. Filardo EJ, Brooks PC, Demming SL, Damsky C, Cheresh DA. Requirement of the NPX motif in the integrin β3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. J Cell Biol. 1995;130:441-450.
13. Clyman RI, McDonald KA, Kramer RH. Integrin receptors on aortic smooth muscle cells mediate adhesion to fibronectin. laminin and collagen. Circ Res. 1990;67:175-186.
14. 3 integrins have different roles in the adhesion and migration of vascular smooth muscle cells on extracellular matrix. Exp Cell Res. 1992;200:272-284.
15. Yamamoto K, Yamamoto M. Cell adhesion receptors for native and denatured type I collugens and fibronectin in rabbit arterial smooth muscle cells in culture. Exp Cell Res. 1994;214:258-263.
16. Slepian MJ, Massia SP. Local delivery of a cyclic RGD peptide inhibits neointimal hyperplasia following balloon injury. Circulation. 1993;88(suppl I):I-372. Abstract.
17. Choi ET, Engel L, Callow AD, Sun S, Trachtenberg J, Santoro S, Ryan US. Inhibition of neointimal hyperplasia by blocking αvjβ integrin with a small peptide antagonist GPenGRGDSPCA. J Vasc Surg, 1994;19:125-134.
18. Matsuno H, Stassen JM, Vermylen J, Deckmyn H. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation. 1994;90:2203-2206.
19. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, on behalf of the EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
20. Ross R, Kariya B. Morphogenesis of vascular smooth muscle in atherosclerosis and cell structure. In: Bohr DF, Somiyo AP, Sparks HY, eds. Handbook of Physiology: The Cardiovascular System, Section 2. 1988. Bethesda, Md: American Physiological Society; 1988:69-91.
21. Dubey RK, Roy A, Overbeck HW. Culture of renal arteriolar smooth muscle cells: mitogenic responses to angiotensin II Circ Res. 1992;71:1143-1152.
22. Slepian MJ, Massia SP, Whitesell L. Pre-conditioning of smooth muscle cells via induction of the heat shock response limits proliferation following mechanical injury. Biochem Biophys Res Commun. 1996;225:600-607.
23. 125I-containing acylating agent. Biochem J. 1973;133:529-539.
24. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest. 1983;44:301-308.
25. Jackson CL, Reidy MA. Basic fibroblast growth factor: its role in the control of smooth muscle cell migration. Am J Pathol. 1993;143:1024-1031.
26. Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-GlyAsp-specific adhesion receptors. Science. 1986;231:1559-1562.
27. Albelda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J. 1990;4:2868-2880.
28. 1 integrin is required for chemotaxis across type I collagen-coated membranes. Am J Pathol. 1994;145:1070-1081.
29. 3 integrin expression in normal and atherosclerotic artery. Circ Res. 1995;77:1129-1135.
30. Hay ED. Role of cell-matrix contacts in cell migration and epithelialmesenchymal transformation. Cell Differ Dev. 1990;32:367-375.
31. Grinell F. Cellular adhesiveness and extracellular substrates. Int Rev Cytol. 1978;53:65-144.
32. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, Schwartz SM, Giachelli CM. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins: role of αvβ3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest. 1995;95:713-724.
33. 3 binds to denatured collagen type I through RGD sites. Biochem Biophys Res Commun. 1992;182:1025-1031.
34. Pierschbacher MD, Ruoslahti E. Influence of stereochemistry of the sequence arg-gly-asp-xaa on binding specificity in cell adhesion. J Biol Chem. 1987;262:17294-17298.
35. Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol. 1993;5:864-868.
36. Gehlsen KR, Davis GE, Sriramarao P. Integrin expression in human melanoma cells with differing invasive and metastatic properties. Clin Exp Metastasis. 1992;10:111-120.
37. Ruggeri Z. von Willebrand factor and fibrinogen. Curr Opin Cell Biol. 1993;5:898-906.
38. Grinell F, Ho CH, Wysocki A. Degradation of fibronectin and vitronectin in chronic wound fluid: analysis by cell blotting, immunoblotting, and cell adhesion assays. J Invest Dermatol. 1992;98:410-416.
39. Vue TL, McKenna PJ, Ohlstein EH, Farach-Carson MC, Butler WT, Johanson K, McDevitt P, Feuerstein GZ, Stadel JM. Osteopontinstimulated vascular smooth muscle cell migration is mediated by β3 integrin. Exp Cell Res. 1994;214:459-464.
40. Dejena ES, Colella S, Conforti G, Abbadini M, Gaboli M, Marchisio PC. Fibronectin and vitronectin regulate the organization of their respective Arg-Gly-Asp adhesion receptors in cultured human endothelial cells. J Cell Biol. 1987;107:1215-1231.
41. Brown MJ, Loew LM. Graded fibronectin receptor aggregation in migrating cells. Cell Motil Cytoskeleton. 1966;34:185-193.
42. Clowes AW, Schwartz SM. Significance of quiescent smooth muscle cell migration in the injured rat carotid artery. Circ Res. 1985;56:139-145.
43. Topol EJ. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Eur Heart J. 1996;17:9-18.
44. 3, blockade with percutaneous coronary intervention. JAMA. 1997;278:479-484.
45. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
46. Nip J, Rabbani SA, Shibata HR, Brodt P. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. J Clin Invest. 1995;95:2096-2103.
47. Edelman ER, Adams DA, Karaovsky MJ. Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc Natl Acad Sci U S A. 1990;87:3773-3777.
48. Slepian MJ, Hubbell JA. Polymeric endoluminal gel paving: hydrogel systems for local barrier creation and site-specific drug delivery. Adv Drug Deliv Rev. 1997;24:11-30.
49. Barker PL, Bullens S, Bunting S, Burdick DJ, Chan KS, Deisher T, Eigenbrot C, Gadek TR, Gantzos R, Lipari MT, Muir CD, Napier MA, Pitti RM, Padua A, Quan C, Stanley M, Struble M, Tom JYK, Burnier JP. Cyclic RGD peptide analogues as anti-platelet anti-thrombotics. J Med Chem. 1992;35:2040-2048.
50. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
51. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.